TY - JOUR
T1 - Interim 2017/18 influenza seasonal vaccine effectiveness
T2 - combined results from five European studies
AU - Rondy, Marc
AU - Kissling, Esther
AU - Emborg, Hanne-Dorthe
AU - Gherasim, Alin
AU - Pebody, Richard
AU - Trebbien, Ramona
AU - Pozo, Francisco
AU - Larrauri, Amparo
AU - McMenamin, Jim
AU - Valenciano, Marta
AU - I-MOVE/I-MOVE+ group
A2 - Fischer, Thea Kølsen
PY - 2018/3
Y1 - 2018/3
N2 - Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
AB - Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
U2 - 10.2807/1560-7917.ES.2018.23.9.18-00086
DO - 10.2807/1560-7917.ES.2018.23.9.18-00086
M3 - Journal article
C2 - 29510782
SN - 1560-7917
VL - 23
JO - Eurosurveillance
JF - Eurosurveillance
IS - 9
ER -